• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc. (Amendment)

    2/14/24 4:52:12 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KPTI alert in real time by email
    SC 13G/A 1 karypharm.htm Ehealth
    
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    
    SCHEDULE 13G
    
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO RULE 13d-2(b)
    
    (AMENDMENT NO. 8)*
    
    Karyopharm Therapeutics Inc.
    (Name of Issuer)
    
    Common Stock
    (Title of Class of Securities)
    
    48576U106
    (CUSIP Number)
    
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)
    
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    
    [ X ] Rule 13d-1(b)
    [     ] Rule 13d-1(c)
    [     ] Rule 13d-1(d)
    
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    
    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
    
    CUSIP No. 48576U106	 	13G	 	Page 2 of 9 Pages
    1.	NAMES OF REPORTING PERSONS OR
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
    
    Patrick Lee, MD
    2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    	(a) [    ]
    (b) [ x ]
    3.	SEC USE ONLY
    
    4.	CITIZENSHIP OR PLACE OF ORGANIZATION
    USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER
    
     0
    	6.	SHARED VOTING POWER
    
    5,102,193
    	7.	SOLE DISPOSITIVE POWER
    
     0
    	8.	SHARED DISPOSITIVE POWER
    
     5,102,193
    9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    
    5,102,193
    10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions) [  ]
    
    11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    
     4.45%
    12.	TYPE OF REPORTING PERSON (see instructions)
    
     IN, HC
    
    
    
    
    
    CUSIP No. 48576U106	 	13G	 	Page 3 of 9 Pages
    1.	NAMES OF REPORTING PERSONS OR
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
    
    Anthony Joonkyoo Yun, MD
    2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    	(a) [    ]
    (b) [ x ]
    3.	SEC USE ONLY
    
    4.	CITIZENSHIP OR PLACE OF ORGANIZATION
     USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER
    
     0
    	6.	SHARED VOTING POWER
    
    5,102,193
    	7.	SOLE DISPOSITIVE POWER
    
     0
    	8.	SHARED DISPOSITIVE POWER
    
     5,102,193
    9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    
    5,102,193
    10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions) [  ]
    
    11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    
    4.45%
    12.	TYPE OF REPORTING PERSON (see instructions)
    
     IN, HC
    
    
    
    
    
    
    
    CUSIP No. 48576U106	 	13G	 	Page 4 of 9 Pages
    1.	NAMES OF REPORTING PERSONS OR
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
    
    Palo Alto Investors LP
    2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    	(a) [    ]
    (b) [ x ]
    3.	SEC USE ONLY
    
    4.	CITIZENSHIP OR PLACE OF ORGANIZATION
    California
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER
    
     0
    	6.	SHARED VOTING POWER
    
    5,102,193
    	7.	SOLE DISPOSITIVE POWER
    
     0
    	8.	SHARED DISPOSITIVE POWER
    
    5,102,193
    9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    
    5,102,193
    10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions) [  ]
    
    11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    
     4.45%
    12.	TYPE OF REPORTING PERSON (see instructions)
    
     OO, IA
    
    
    
    
    
    CUSIP No. 48576U106	 	13G	 	Page 5 of 9 Pages
    1.	NAMES OF REPORTING PERSONS OR
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
    
    PAI LLC
    2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    	(a) [    ]
    (b) [ x ]
    3.	SEC USE ONLY
    
    4.	CITIZENSHIP OR PLACE OF ORGANIZATION
    California
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER
    
     0
    	6.	SHARED VOTING POWER
    
    5,102,193
    	7.	SOLE DISPOSITIVE POWER
    
     0
    	8.	SHARED DISPOSITIVE POWER
    
     5,102,193
    9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    
     5,102,193
    10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions) [  ]
    
    11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    
     4.45%
    12.	TYPE OF REPORTING PERSON (see instructions)
    
     OO, IA
    
    
    
    
    
    CUSIP No. 48576U106	 	13G	 	Page 6 of 9 Pages
    
    Item 1.
    	(a)	Name of Issuer
    
    Karyopharm Therapeutics Inc.
    
     	(b)	Address of Issuer's Principal Executive Offices
    
    85 Wells Avenue, 2nd Floor, Newton, MA 02459
    
    Item 2.
    	(a)	Name of Person Filing
    
    Palo Alto Investors LP ("PAI")
    PAI LLC ("PAI GP")
    Patrick Lee, MD ("Dr. Lee")
    Anthony Joonkyoo Yun, MD ("Dr. Yun")
    
    (collectively, the "Filers").
    
     	(b)	The address of the principal place of the Filers:
    
    470 University Avenue, Palo Alto, CA 94301
    
    
     	(c)	 For citizenship of Filers, see Item 4 of the cover sheet for each Filer.
    
    
     	(d)	Title of Class of Securities
    
    Common Stock
    
     	(e)	CUSIP Number
    
    48576U106
    
    Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    
     	(a)	[  ]	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    
     	(b)	[  ]	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    
     	(c)	[  ]	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    
    
    
     	(d)	[  ]	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    
    
    
    
     	(e)	[x]	An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (as to PAI)
    
    
    
    
     	(f)	[  ]	An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    
    
    
    
    
    
     	(g)	[x] 	A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (as to Dr. Lee and Dr. Yun)
    
     	(h)	[  ]	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    
     	(i)	[  ]	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    
     	(j)	[  ]	Group, in accordance with 240.13d-1(b)(1)(ii)(J).
    CUSIP No. 48576U106	 	13G	 	Page 7 of 9 Pages
    
    
    Item 4. Ownership.
    
    See Items 5-9 and 11 of the cover page for each Filer.
    
    Item 5. Ownership of Five Percent or Less of a Class.
    
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ].
    
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    
    PAI is a registered investment adviser and investment adviser of investment limited partnerships, and is the investment adviser to other investment funds. PAI GP is the general partner of investment limited partnerships. PAI's clients have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.
    
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
    
    N/A
    
    Item 8. Identification and Classification of Members of the Group.
    
    Dr. Lee and Dr. Yun co-manage PAI. The Filers are filing this Schedule 13G jointly, but not as members of a group, and each of them expressly disclaims membership in a group. Each Filer disclaims beneficial ownership of the Stock except to the extent of that Filer's pecuniary interest therein.
    
    
    Item 9. Notice of Dissolution of Group.
    
    N/A
    
    
    
    
    CUSIP No. 48576U106	 	13G	 	Page 8 of 9 Pages
    
    Item 10. Certification.
    
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    
    Exhibits.
    
    Exhibit A Joint Filing Agreement.
    
    
    SIGNATURE
    
    
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    
    Dated: February 14, 2024
    
    
    
    
    PALO ALTO INVESTORS LP
    
    By: /s/ Angela Nguyen-Dinh, Chief Compliance Officer
    
    PAI LLC
    
    By: /s/ Patrick Lee, MD
    
    
    /s/ Anthony Joonkyoo Yun, MD
    
    
    CUSIP No. 48576U106	 	13G	 	Page 9 of 9 Pages
    
    EXHIBIT A
    AGREEMENT REGARDING JOINT FILING
    OF STATEMENT ON SCHEDULE 13D OR 13G
    
    The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G (and any amendments or supplements thereto) required under section 13(d) of the Securities Exchange Act of 1934, as amended, in connection with purchases and sales by the undersigned of the securities of any issuer until such time as the undersigned file with the SEC a statement terminating this Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G. For that purpose, the undersigned hereby constitute and appoint Palo Alto Investors, LP, a California limited partnership, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases and sales, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present, until such time as the undersigned file with the SEC a statement terminating this Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.
    
    Dated: February 14, 2024
    
    
    
    PALO ALTO INVESTORS LP
    
    By: /s/ Angela Nguyen-Dinh, Chief Compliance Officer
    
    PAI LLC
    
    By: /s/ Patrick Lee, MD
    
    
    /s/ Anthony Joonkyoo Yun, MD
    
    
    
    
    
    
    Get the next $KPTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KPTI

    DatePrice TargetRatingAnalyst
    1/19/2023$8.00Overweight
    Piper Sandler
    11/4/2022$7.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    3/8/2022$12.00 → $8.00Sector Perform
    RBC Capital
    3/2/2022$8.00 → $6.00Market Perform
    SVB Leerink
    2/9/2022$8.00Underweight → Neutral
    JP Morgan
    1/10/2022$6.00 → $8.00Market Perform
    SVB Leerink
    12/9/2021$8.00 → $9.00Sector Perform
    RBC Capital
    11/19/2021$27.00 → $10.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $KPTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on Karyopharm Therapeutics with a new price target

      Piper Sandler initiated coverage of Karyopharm Therapeutics with a rating of Overweight and set a new price target of $8.00

      1/19/23 7:43:39 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded Karyopharm Therapeutics from Sector Perform to Outperform and set a new price target of $10.00 from $7.00 previously

      11/4/22 7:23:40 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital reiterated coverage on Karyopharm Therapeutics with a new price target

      RBC Capital reiterated coverage of Karyopharm Therapeutics with a rating of Sector Perform and set a new price target of $8.00 from $12.00 previously

      3/8/22 7:29:51 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $KPTI
    Leadership Updates

    Live Leadership Updates

    See more

    $KPTI
    SEC Filings

    See more
    • Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

      SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

      11/14/24 4:22:08 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

      SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

      11/12/24 3:50:51 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

      SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

      11/4/24 11:49:19 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

      NEWTON, Mass., Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025. In this role, Ms. Macomber will be responsible for leading and directing the financial activities of the Company. "Lori is an outstanding addition to the Karyopharm team," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "She brings extensive experience in strategic financial management and operations, which will be critical as we execute on our strategy to grow

      1/2/25 7:00:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

      NEWTON, Mass., Dec. 9, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications. "We are thrilled to have Brendan on board as we work towards delivering on and communicating important milestones for our organization in 2025," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "Brendan's experience as a former sell-side analyst, advisor to biopharmaceutical companies and proven ability to develop strong investor relations and corporate communications programs wi

      12/9/24 8:00:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

      NEWTON, Mass., Nov. 20, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Kristin Abate, the Company's Vice President, Accounting, Corporate Controller and Assistant Treasurer has been appointed the Company's Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024. Ms. Abate, who has also served as the Company's interim principal financial officer and interim principal accounting officer since November 6, 2024, has been designated as the Company's principal accounting officer, effective November 20, 2024. Ms. Abate will continue to serve as t

      11/20/24 4:05:00 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)

      5/29/25 4:28:22 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Karyopharm Therapeutics Inc.

      10-Q - Karyopharm Therapeutics Inc. (0001503802) (Filer)

      5/12/25 4:14:43 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)

      5/12/25 4:06:37 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPTI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

      NEWTON, Mass., May 19, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 2025 RBC Capital Markets Global Healthcare Conference in a fireside chat on Wednesday, May 21 at 10:00 a.m. ET in New York, NY. A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investors.karyopharm.com/events-presentations, and will be available for replay following the event. About Karyopharm Therapeutics Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is a comme

      5/19/25 7:00:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

      NEWTON, Mass., May 14, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced its abstract has been selected for a poster presentation at the 2025 European Hematology Association Annual Meeting (EHA) being held June 12-15 in Milan, Italy. The abstract contains data on selinexor monotherapy in a hard-to-treat, heavily pretreated myelofibrosis patient population from the Phase 2 XPORT-MF-035 trial. "We are encouraged by our new data in hard-to-treat myelofibrosis patients where we observed spleen volume reduction, symptom improvement, hemoglobin stabilization and evidence of disease modificat

      5/14/25 9:31:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

      – New Randomized Phase 2 Monotherapy Data from XPORT-MF-035 Trial in a Hard-to-Treat Patient Population Further Strengthens Conviction in Selinexor's Potential in Combination with Ruxolitinib in JAKi-Naïve Myelofibrosis in Ongoing Phase 3 SENTRY Trial – – Phase 3 SENTRY Trial Passed Planned Futility Analysis; Trial is Approximately 80% Enrolled with Target Enrollment Expected in June/July 2025 – – Demand for XPOVIO® (selinexor) Increased 5% in the First Quarter of 2025 Compared to the First Quarter of 2024; Total Revenue was $30.0 Million; U.S. XPOVIO® Net Product Revenue of $21.1 Million was Adversely Impacted by a $5.0 Million Increase in the Product Return Reserve due to Atypical Returns

      5/12/25 4:05:00 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Su Zhen

      4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

      5/29/25 4:15:13 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Pakianathan Deepika

      4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

      5/29/25 4:13:39 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Oliger Christy J.

      4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

      5/29/25 4:12:06 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPTI
    Financials

    Live finance-specific insights

    See more
    • Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

      – New Randomized Phase 2 Monotherapy Data from XPORT-MF-035 Trial in a Hard-to-Treat Patient Population Further Strengthens Conviction in Selinexor's Potential in Combination with Ruxolitinib in JAKi-Naïve Myelofibrosis in Ongoing Phase 3 SENTRY Trial – – Phase 3 SENTRY Trial Passed Planned Futility Analysis; Trial is Approximately 80% Enrolled with Target Enrollment Expected in June/July 2025 – – Demand for XPOVIO® (selinexor) Increased 5% in the First Quarter of 2025 Compared to the First Quarter of 2024; Total Revenue was $30.0 Million; U.S. XPOVIO® Net Product Revenue of $21.1 Million was Adversely Impacted by a $5.0 Million Increase in the Product Return Reserve due to Atypical Returns

      5/12/25 4:05:00 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

      -- Conference Call Scheduled for Monday, May 12, 2025, at 4:30 p.m. ET -- NEWTON, Mass., May 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2025 financial results on Monday, May 12, 2025. Karyopharm's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, May 12, 2025, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeu

      5/8/25 4:05:00 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

      – Total Revenue of $145 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $113 Million for Full Year 2024 – – Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Naïve Myelofibrosis Anticipated in 2H 2025; Company on Track to Complete Enrollment in 1H 2025 – – Company Announces Update to Phase 3 XPORT-EC-042 Trial of Selinexor as Maintenance Therapy in Advanced or Recurrent TP53 Wild-Type Endometrial Cancer. Following Dialogue with the FDA Regarding the Evolving Treatment Landscape, Trial to Focus Enrollment on Patients with Either pMMR Tumors or Patients with dMMR Tumors that are Medically Ineligible for Checkp

      2/19/25 7:30:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care